EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Efficacy of Tegoprazan in Patients With Functional Dyspepsia: A Prospective, Multicenter, Single-arm Study

Cheal Wung Huh iD, Young Hoon Youn iD, Da Hyun Jung, Ra Ri Cha, Yeon Ji Kim, Kyoungwon Jung, Kyung Ho Song, Ki Bae Bang, Chung Hyun Tae, Soo In Choi, Cheol Min Shin, Functional Dyspepsia Research Group Under the Korean Society of Neurogastroenterology and Motility

Journal of Neurogastroenterology and Motility · 30.07.2024 · 30 (3) · 313-321

DOI: 10.5056/jnm23150 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Neurogastroenterology and Motility, online erschienen am 04.05.2024. Verfasst von Cheal Wung Huh und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: HK inno.N Corp..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aims: Acid-suppressive drugs, such as proton pump inhibitors (PPIs), are treatment options for functional dyspepsia (FD). However, the efficacy of potassium-competitive acid blockers (P-CABs) in treating FD has not yet been established. This prospective multicenter clinical trial-based study aimed to assess the efficacy and safety of tegoprazan as a P-CAB treatment in patients with FD.

Methods

FD was diagnosed using the Rome IV criteria. All patients received tegoprazan 50 mg once daily for 8 weeks. Dyspeptic symptoms were assessed using a dyspepsia symptom questionnaire (5-point Likert scale, Nepean Dyspepsia Index-Korean [NDI-K], and gastroesophageal reflux disease-health-related quality of life [GERD-HRQL]). The main outcome was satisfactory symptom relief rates at 8 weeks.

Results

In this study, from the initial screening of 209 patients, 173 were included in the per-protocol set analysis. Satisfactory symptom relief rates at 8 and 4 weeks were 86.7% and 74.6%, respectively. In addition, the NDI-K and GERD-HRQL scores significantly improved at 8 and 4 weeks compared with the baseline scores. The efficacy of tegoprazan was not influenced by the FD subtype or Helicobacter pylori status. In patients with overlapping FD and GERD, there was a greater improvement in the NDI-K and GERD-HRQL scores than in patients with FD symptoms only. No serious drug-related adverse events occurred during this study.

Conclusion

Tegoprazan (50 mg) administered once daily provided satisfactory symptom relief for FD.

Schlagwörter

Stichwörter der Autor:innen

EfficacyFunctional dyspepsiaPotassium-competitive acid blockerSafety

Autor:innen und Institutionen

  • Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
  • Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
  • Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
  • Department of Internal Medicine, Gyeongsang National University Changwon Hospital, Gyeongsang National University School of Medicine, Jinju, Gyeongsangnam-do, Korea.
  • Department of Internal Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea.

ORCID-Profile: Cheal Wung Huh, Young Hoon Youn

Förderung

  • HK inno.N Corp.

Zitieren

APA

Huh, C. W., Youn, Y. H., Jung, D. H., Cha, R. R., Kim, Y. J., Jung, K., Song, K. H., Bang, K. B., Tae, C. H., Choi, S. I., Shin, C. M., & Functional Dyspepsia Research Group Under the Korean Society of Neurogastroenterology and Motility (2024). Efficacy of Tegoprazan in Patients With Functional Dyspepsia: A Prospective, Multicenter, Single-arm Study. Journal of Neurogastroenterology and Motility, 30(3), 313-321. https://doi.org/10.5056/jnm23150

Vancouver

Huh CW, Youn YH, Jung DH, Cha RR, Kim YJ, Jung K, et al. Efficacy of Tegoprazan in Patients With Functional Dyspepsia: A Prospective, Multicenter, Single-arm Study. Journal of Neurogastroenterology and Motility. 2024;30(3):313-321. doi:10.5056/jnm23150

BibTeX
@article{Huh2024,
  author = {Huh, Cheal Wung and Youn, Young Hoon and Jung, Da Hyun and Cha, Ra Ri and Kim, Yeon Ji and Jung, Kyoungwon and Song, Kyung Ho and Bang, Ki Bae and Tae, Chung Hyun and Choi, Soo In and Shin, Cheol Min and Functional Dyspepsia Research Group Under the Korean Society of Neurogastroenterology and Motility, Functional Dyspepsia Research Group Under the Korean Society of Neurogastroenterology and Motility},
  title = {Efficacy of Tegoprazan in Patients With Functional Dyspepsia: A Prospective, Multicenter, Single-arm Study},
  journal = {Journal of Neurogastroenterology and Motility},
  year = {2024},
  volume = {30},
  number = {3},
  pages = {313--321},
  doi = {10.5056/jnm23150}
}
Kostenlos starten →